Article
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
Investigational new drugs - 1 Jun 2012
Oh Do-Youn, Lee Keun Wook, Lee Kyung-Hee, Sohn Chang-Hak, Park Young Suk, Zang Dae Young, Ryoo Hun-Mo, Song Hong-Suk, Kim Jin-Soo, Kang Hye-Jin, Kim Bong-Seog, Bang Yung-Jue
Abstract excerpt
BACKGROUND: To confirm the efficacy and toxicity of Erlotinib in combination with Gemcitabine and Capecitabine when used as a first-line therapy in metastatic/recurrent pancreatic cancer (PC). METHODS: Locally advanced PC was excluded. Erlotinib was given at a dose of 100 mg daily from D1 to D28. 1000 mg/m(2) of gemcitabine was given on D1,8,15 and 1660 mg/m(2)/day of capecitabine was given from D1 to 21,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.